Regulatory filing 📈 Stocks 🌍 United States

Planet Green Holdings Subsidiary Acquires Lactoferrin Tablet Rights

Planet Green Holdings subsidiary Taihe Bio acquired rights to a registered lactoferrin, bovine colostrum, and vitamin C chewable tablet, utilizing an asset-light contract manufacturing strategy to target the Chinese immune-health market.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 0 Bullish, 0 Bearish, 1 Neutral. Strongest signal: PLAG → 2/10 (50% confidence).

📊 Affected Assets (1)

PLAG
Neutral 🤖 50%
📅 Short-term 🌍 US · Explicit

Subsidiary Taihe Bio agreed to acquire the formulation, production technology and Chinese health food registration rights for a lactoferrin, bovine colostrum and vitamin C chewable tablet. The 8-K discloses no purchase price, no revenue figures and no financial guidance, so the deal cannot be quantified as materially positive or negative. It extends the previously announced lactoferrin strategy and remains subject to SAMR approval of the registration transfer.

Catalysts
  • • Technology transfer agreement with Harbin Aikesailun Biotechnology announced November 17, 2026
  • • Pending joint application to SAMR to transfer the Chinese health food registration certificate to Taihe Bio
Risk Factors
  • • No purchase price or financial terms are disclosed, so the cost and expected return are unknown
  • • Transfer of the registration certificate remains subject to regulatory approval

🧭 Full analysis of these assets

🎯 Key Takeaways

  • Taihe Bio acquired the formulation, production technology, and Chinese health food registration rights for a chewable tablet from Harbin Aikesailun Biotechnology.
  • The acquisition allows Planet Green to bypass the registration process for the product, which is already approved for sale in China.
  • The company plans to use third-party contract manufacturers to produce the tablets, avoiding the capital expenditure of building its own facilities.
  • The global lactoferrin market is projected to grow from approximately US$278 million in 2026 to approximately US$519 million by 2034.

📝 Executive Summary

Planet Green Holdings Corp. subsidiary Taihe Bio has entered a technology transfer agreement with Harbin Aikesailun Biotechnology to acquire the formulation and registration rights for an immune-support chewable tablet. The product combines lactoferrin, bovine colostrum, and vitamin C, with the company planning an asset-light manufacturing model to enter the Chinese health food market.

❓ FAQ

What did Planet Green announce?

Its subsidiary Taihe Bio signed an agreement to acquire the formulation, production know-how and Chinese health food registration rights for a lactoferrin, bovine colostrum and vitamin C chewable tablet from Harbin Aikesailun Biotechnology.

Does this deal have a stated price and is it done?

No price or financial terms are mentioned in the filing, and the registration certificate transfer still needs approval from China's SAMR before commercial production can begin.